India markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
388.44+4.92 (+1.28%)
At close: 4:00PM EDT
388.44 0.00 (0.00%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close383.52
Open387.19
Bid386.72 x 1200
Ask392.88 x 900
Day's range381.65 - 390.47
52-week range223.25 - 468.55
Volume2,831,488
Avg. volume1,739,749
Market cap58.482B
Beta (5Y monthly)0.42
PE ratio (TTM)20.14
EPS (TTM)19.29
Earnings date20-Jul-2021 - 26-Jul-2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est405.41
  • Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
    GlobeNewswire

    Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

    Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited treatment optionsPositive Phase 2 LILAC study efficacy results support the further evaluation of BIIB059 in SLE CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 stu

  • Yahoo Finance Video

    Influencers with Andy Serwer: David Ricks

    In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.